Passa al contenuto
Merck
Tutte le immagini(2)

Key Documents

O9512

Sigma-Aldrich

Oxaliplatin

powder

Sinonimo/i:

[SP-4-2-(1R-trans)]-(1,2-Cyclohexanediamine-N,N′)[ethanedioata(2--)-O,O’]platinum

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C8H14N2O4Pt
Numero CAS:
Peso molecolare:
397.29
Numero MDL:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Forma fisica

powder

Livello qualitativo

Ideatore

Sanofi Aventis

Temperatura di conservazione

2-8°C

Stringa SMILE

O=C1O[Pt]OC1=O.N[C@@H]2CCCC[C@H]2N

InChI

1S/C6H14N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-6H,1-4,7-8H2;(H,3,4)(H,5,6);/q;;+2/p-2/t5-,6-;;/m1../s1
ZROHGHOFXNOHSO-BNTLRKBRSA-L

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Oxaliplatin has been used:
  • as a chemotherapeutic agent in colon rectal adenocarcinoma SW480 cells by cell viability assay
  • for monitoring cell survival in hepatocellular carcinoma HepG2 and HepG2/R cells by MTT assay
  • to determine the growth inhibitory effect on human breast adenocarcinoma MDA-MB-231 cells

Azioni biochim/fisiol

Oxaliplatin a platinum analogue, causes DNA damage and cell death by binding to DNA and forming inter and intrastrand crosslinks preventing replication and transcription. Oxaliplatin is an anti-tumor agent with activity against colorectal cancer; cytotoxicity follows the formation of adducts with DNA. Oxaliplatin is an approved drug for treating colorectal cancer. It is an active ingredient in FOLFOX (Folinic acid:5-FU:oxaliplatin in the ratio 1:10:1 of micromolar concentrations respectively). Oxaliplatin causes both acute and chronic neurotoxicity in patients in a dose dependent manner and is reversible either by reducing or stopping the drug.

Caratteristiche e vantaggi

This compound is a featured product for ADME Tox and Apoptosis research. Discover more featured ADME Tox and Apoptosis products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazardCorrosion

Avvertenze

Danger

Classi di pericolo

Carc. 2 - Eye Dam. 1 - Lact. - Muta. 2 - Repr. 1B - Resp. Sens. 1B - Skin Sens. 1 - STOT RE 1

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

SUMOylation alterations are associated with multidrug resistance in hepatocellular carcinoma
Qin Y, et al.
Molecular Medicine Reports, 9(3), 877-881 (2014)
Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study
Votanopoulos KI, et al.
Annals of Surgical Oncology, 1-9 (2018)
Expression of an oncogenic BARD1 splice variant impairs homologous recombination and predicts response to PARP-1 inhibitor therapy in colon cancer
Ozden O, et al.
Scientific Reports, 6, 26273-26273 (2016)
Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue
Jamieson SMF, et al.
Molecular Pain, 5(1), 66-66 (2009)
Bernard Nordlinger et al.
The Lancet. Oncology, 14(12), 1208-1215 (2013-10-15)
Previous results of the EORTC intergroup trial 40983 showed that perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) increases progression-free survival (PFS) compared with surgery alone for patients with initially resectable liver metastases from colorectal cancer. Here we present

Articoli

DNA damage and repair mechanism is vital for maintaining DNA integrity. Damage to cellular DNA is involved in mutagenesis, the development of cancer among others.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.